Skip to main content
Clinical Trials/NCT00956488
NCT00956488
Completed
Phase 1

Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis

Wake Forest University Health Sciences1 site in 1 country9 target enrollmentSeptember 2008

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Amyotrophic Lateral Sclerosis
Sponsor
Wake Forest University Health Sciences
Enrollment
9
Locations
1
Primary Endpoint
Twenty Five Foot Walk Test (25FWT)
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this study is to find out if supervised exercise training using a treadmill with partial weight support is safe and has an impact on gait and function of persons with Amyotrophic lateral sclerosis.

Detailed Description

Twenty ALS patients who are independent in their transfer with assistive devise such as walker, cane, or AFO will be offered the opportunity to participate in this study. 20 subjects will be enrolled at Carolinas ALS/Neuromuscular Center at the Carolinas HealthCare System. Eligible subjects will return for 26 sessions, each lasting between 1-2 hours. At Session 1 (4 weeks pre-treatment), assessments of muscle strength, spasticity, gait, and balance will be performed, which will take between 30-60 minutes. At Sessions 2-25, patients will do supported treadmill ambulation training at a very low speed 3 times a week for 6 weeks under the supervision of the physical therapist. Each session will have 30 minutes of direct ambulation with the suspension system and treadmill over a 60 minute period of time. Additionally, at sessions 13 and 26 (4 and 8 weeks post-treatment), the assessments of muscle strength, spasticity, gait, and balance will be repeated. Needle EMG to assess denervation potential will be performed at base line and at the conclusion of the study. The study will last a total of 26 weeks for each patient.

Registry
clinicaltrials.gov
Start Date
September 2008
End Date
September 2010
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Clinically probable or definite diagnosis of ALS/MND
  • Able to stand independently and ambulate for six minutes with their assistive devices
  • Able to complete the 25 foot walk in less than 1 minute
  • Vital Capacity of over 65% predicted
  • 25 to 75 years of age
  • Not a pregnant woman
  • Able to provide informed consent and to comply with training and assessment procedures

Exclusion Criteria

  • Unstable angina or severe left main coronary disease
  • End-stage congestive heart failure
  • Severe valvular heart disease
  • Malignant or unstable arrhythmias
  • Elevated resting blood pressure (systolic, 200mmHg; diastolic, 110mmHg)
  • Large or expanding aortic aneurysm
  • Known cerebral aneurysm or recent intracranial bleed
  • Uncontrolled or end-stage systemic disease
  • Acute retinal hemorrhage or recent ophthalmologic surgery
  • Acute or unstable musculoskeletal injury

Outcomes

Primary Outcomes

Twenty Five Foot Walk Test (25FWT)

Time Frame: baseline, after 4 weaks and 8 weaks post training

The Six-Minute Walk Test (6MWT)

Time Frame: baseline, after 4 weaks and 8 weaks post training

Fatigue severity scale (FSS)

Time Frame: baseline, after 4 weaks and 8 weaks post training

Secondary Outcomes

  • Muscle strength(baseline, after 4 weaks and 8 weaks post training)
  • ALS functional rating scale (ALSFRS-R)(baseline, after 4 weaks and 8 weaks post training)
  • Vital Capacity(baseline, after 4 weaks and 8 weaks post training)
  • Beck Depression Inventory (BDI)(baseline, after 4 weaks and 8 weaks post training)

Study Sites (1)

Loading locations...

Similar Trials